FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202964100> ?p ?o ?g. }

• W3202964100 abstract "At the time of writing, Israel is experiencing a new wave of SARS coronavirus 2 (SARS-CoV-2) infection and Covid-19 disease despite having a high vaccine uptake with both doses of Pfizer/BioNTech mRNA vaccine. This has prompted UK politicians to propose a booster dose for adults in this country. It may therefore be timely to remind them about what we have learned over the years about the principles of vaccinology in order to inform their decisions more effectively. Successful vaccines prevent disease.1 They may also prevent transmission of virus between individuals depending on the characteristics of the vaccine used. For example, killed poliovirus vaccine effectively prevents disease by providing IgG antibodies that block the ability of poliovirus in the gastrointestinal tract to use the bloodstream to reach the anterior horn cells of the spinal cord. Live, attenuated poliovirus vaccine likewise provides these IgG antibodies to protect against disease but also induces secretory IgA antibodies in the gastrointestinal and respiratory tracts. This local immunity is responsible for reducing transmission of virus from person to person so allowing oral polio vaccine, unlike its killed alternative, to interrupt transmission of virus in the community. This was illustrated clearly in the late 1980s when an outbreak in Israel of wild poliovirus infection was controlled only once oral vaccine was added to the routine schedule of killed vaccine.2 The licensed SARS-CoV-2 vaccines based on mRNA and recombinant adenovirus technologies are remarkably potent at preventing Covid-19, especially the deaths that result from over-activity of the immune system.3 However, in terms of interrupting transmission of SARS-CoV-2, they are behaving more like killed polio vaccine than the live attenuated version. They have some useful activity (perhaps 60%) against transmission of virus, but the consequences of this for vaccine effectiveness in a community need to be related to the strains of SARS-CoV-2 currently circulating. The original strain had a basic reproductive number of around 2.5, meaning that a vaccine that reduced community transmission by 60% would induce herd immunity. However, the emergence of other strains, particularly Delta, has provided viruses with a basic reproductive number of approximately 5 that would require 90% reduction in transmission in order to achieve herd immunity.4 This explains why Delta infection has continued to circulate in Israel despite a very high uptake of vaccine. Just as SARS-CoV-2 can reinfect after natural infection,5 it can reinfect after vaccine-induced immunity, especially if individuals do not heed advice about social distancing and so transmit relatively large inocula of virus. Importantly, this phenomenon of transmission within a highly immunised population is directly attributable to the concept of herd immunity and has nothing to do with strains of virus that evade vaccine induced immunity.6 It can thus be seen that giving booster doses of the original vaccines, or those designed to confer protective immunity against the variants that have genetic changes in the Spike gene, will not be an appropriate way forward. So, what should be done instead? Applying the poliovirus concept to SARS-CoV-2 suggests that efficient induction of IgG antibodies may be very effective against disease but require alternative ways of inducing secretory antibodies. A search on Pubmed for ‘secretory IgA AND Covid-19 vaccines’ revealed only two publications, both dealing with IgA in breast milk.7, 8 Clearly, more work is needed on secretory IgA antibodies against SARS-CoV-2 in the respiratory tract. Vaccine developers should examine whether any of the now many types of vaccine currently in development produce high levels of secretory IgA antibodies. Those that do, could be tested in individuals already immunised with licensed vaccines. The example of poliovirus is again instructive here, with both killed and live vaccines currently used in immunisation schedules.2 At least two novel approaches should also be considered. The first is to develop and deploy live attenuated vaccines. If given as a booster to those already immunised with vaccines based on mRNA or recombinant adenovirus platforms, the precedent of varicella-zoster virus vaccine must then be remembered. The shingles vaccine requires a high dose of virus (approximately 13 times more plaque forming units) of the same strain of live attenuated vaccine given to prevent chickenpox in seronegatives in order to overcome pre-existing antibody levels in those with prior natural chickenpox.9 The second is to develop a non-replicating vaccine to be given intranasally, or perhaps orally, to stimulate mucosal IgA antibodies. It is clear that the objective of controlling the spread of SARS-CoV-2 will be a long haul endeavour that will be aided by learning from past examples of successful vaccinology. The rapid development of the currently licensed vaccines has been a major achievement in terms of preventing disease and death, but the answer to the distinct problem of transmission of virus is not necessarily more of the same. I personally see no reason for doses of the current vaccines to be given routinely in the UK to people with normal immunity. Instead, they should be donated to Covax for deployment in other countries because, as stated eloquently elsewhere, no-one will be safe until everyone is safe.10" @default.
• W3202964100 created "2021-10-11" @default.
• W3202964100 creator A5027717859 @default.
• W3202964100 date "2021-10-05" @default.
• W3202964100 modified "2023-10-16" @default.
• W3202964100 title "Protection offered by SARS coronavirus 2 vaccines against disease and infection" @default.
• W3202964100 cites W1624653133 @default.
• W3202964100 cites W2079737165 @default.
• W3202964100 cites W2131041950 @default.
• W3202964100 cites W3039491047 @default.
• W3202964100 cites W3165369455 @default.
• W3202964100 cites W3173233238 @default.
• W3202964100 cites W3185220681 @default.
• W3202964100 cites W3192259771 @default.
• W3202964100 cites W3195157781 @default.
• W3202964100 doi "https://doi.org/10.1002/rmv.2303" @default.
• W3202964100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34611953" @default.
• W3202964100 hasPublicationYear "2021" @default.
• W3202964100 type Work @default.
• W3202964100 sameAs 3202964100 @default.
• W3202964100 citedByCount "0" @default.
• W3202964100 crossrefType "journal-article" @default.
• W3202964100 hasAuthorship W3202964100A5027717859 @default.
• W3202964100 hasBestOaLocation W32029641001 @default.
• W3202964100 hasConcept C104317684 @default.
• W3202964100 hasConcept C116675565 @default.
• W3202964100 hasConcept C119599485 @default.
• W3202964100 hasConcept C126322002 @default.
• W3202964100 hasConcept C127413603 @default.
• W3202964100 hasConcept C159047783 @default.
• W3202964100 hasConcept C159654299 @default.
• W3202964100 hasConcept C203014093 @default.
• W3202964100 hasConcept C22070199 @default.
• W3202964100 hasConcept C2522874641 @default.
• W3202964100 hasConcept C2777648638 @default.
• W3202964100 hasConcept C2779134260 @default.
• W3202964100 hasConcept C2779341262 @default.
• W3202964100 hasConcept C2779631682 @default.
• W3202964100 hasConcept C2908689829 @default.
• W3202964100 hasConcept C3008058167 @default.
• W3202964100 hasConcept C4870876 @default.
• W3202964100 hasConcept C524204448 @default.
• W3202964100 hasConcept C54602769 @default.
• W3202964100 hasConcept C55493867 @default.
• W3202964100 hasConcept C60987743 @default.
• W3202964100 hasConcept C71924100 @default.
• W3202964100 hasConcept C761482 @default.
• W3202964100 hasConcept C86803240 @default.
• W3202964100 hasConcept C8891405 @default.
• W3202964100 hasConceptScore W3202964100C104317684 @default.
• W3202964100 hasConceptScore W3202964100C116675565 @default.
• W3202964100 hasConceptScore W3202964100C119599485 @default.
• W3202964100 hasConceptScore W3202964100C126322002 @default.
• W3202964100 hasConceptScore W3202964100C127413603 @default.
• W3202964100 hasConceptScore W3202964100C159047783 @default.
• W3202964100 hasConceptScore W3202964100C159654299 @default.
• W3202964100 hasConceptScore W3202964100C203014093 @default.
• W3202964100 hasConceptScore W3202964100C22070199 @default.
• W3202964100 hasConceptScore W3202964100C2522874641 @default.
• W3202964100 hasConceptScore W3202964100C2777648638 @default.
• W3202964100 hasConceptScore W3202964100C2779134260 @default.
• W3202964100 hasConceptScore W3202964100C2779341262 @default.
• W3202964100 hasConceptScore W3202964100C2779631682 @default.
• W3202964100 hasConceptScore W3202964100C2908689829 @default.
• W3202964100 hasConceptScore W3202964100C3008058167 @default.
• W3202964100 hasConceptScore W3202964100C4870876 @default.
• W3202964100 hasConceptScore W3202964100C524204448 @default.
• W3202964100 hasConceptScore W3202964100C54602769 @default.
• W3202964100 hasConceptScore W3202964100C55493867 @default.
• W3202964100 hasConceptScore W3202964100C60987743 @default.
• W3202964100 hasConceptScore W3202964100C71924100 @default.
• W3202964100 hasConceptScore W3202964100C761482 @default.
• W3202964100 hasConceptScore W3202964100C86803240 @default.
• W3202964100 hasConceptScore W3202964100C8891405 @default.
• W3202964100 hasIssue "1" @default.
• W3202964100 hasLocation W32029641001 @default.
• W3202964100 hasLocation W32029641002 @default.
• W3202964100 hasLocation W32029641003 @default.
• W3202964100 hasOpenAccess W3202964100 @default.
• W3202964100 hasPrimaryLocation W32029641001 @default.
• W3202964100 hasRelatedWork W1502538658 @default.
• W3202964100 hasRelatedWork W1874486123 @default.
• W3202964100 hasRelatedWork W1986363001 @default.
• W3202964100 hasRelatedWork W2076152073 @default.
• W3202964100 hasRelatedWork W2169451742 @default.
• W3202964100 hasRelatedWork W2899415274 @default.
• W3202964100 hasRelatedWork W3019647694 @default.
• W3202964100 hasRelatedWork W4200620235 @default.
• W3202964100 hasRelatedWork W4220948925 @default.
• W3202964100 hasRelatedWork W1989164437 @default.
• W3202964100 hasVolume "32" @default.
• W3202964100 isParatext "false" @default.
• W3202964100 isRetracted "false" @default.
• W3202964100 magId "3202964100" @default.
• W3202964100 workType "article" @default.